RxDoctor Payments Data

Stephanie McGuire, APRN

Nurse Practitioner · Berea, KYNPI 1770861254

Payments from drug & device makers

$934in general payments, 2019–2025

Across 31 payments — averaging $30.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$322
  • AstraZeneca$163
  • Otsuka America Pharmaceutical, Inc.$122
  • Dexcom, Inc.$83
  • Corcept Therapeutics$39
  • Indivior Inc.$39
  • plus $167 from 6 others

What the payments were for

  • Food & beverage$934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$934 in reported general payments places this provider in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$455
Medicare patients
18
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$22,580
OzempicSemaglutide24$21,888
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl70$10,592
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,359
Breo ElliptaFluticasone/Vilanterol12$4,758
Albuterol Sulfate HfaAlbuterol Sulfate29$807
Pantoprazole Sodium43$384
Atorvastatin Calcium48$366
Gabapentin28$324
Amlodipine Besylate50$321
Quetiapine Fumarate14$310
Rosuvastatin Calcium17$302
Famotidine22$294
Estradiol15$290
Levothyroxine Sodium26$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$322$22,58014 claims
Novo NordiskOzempic$38$21,88824 claims
AstraZenecaBreztri Aerosphere$163$10,35913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Berea

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →